XenoPort Inc

XenoPort — Proxy Contest (May 2014)

49 slides from XenoPort's proxy contest presentation, May 21, 2014

  1. Slide 1: The Right Strategy and Board to Build Stockholder Value

    Exhibit 99.1 The Right Strategy and Board to Build Stockholder Value © Copyright 2014 XenoPort, Inc. All rights reserved. NASDAQ:XNPT

  2. Slide 2: Safe Harbor Language

    Safe Harbor Language These slides and the accompanying oral presentation by XenoPort, Inc. contain forward-looking statements that involve risks and uncertainties, including statements relating to the commercial opportunity and value proposition for HORZIANT; potential future sales and commercializa

  3. Slide 3: Additional Information

    Additional Information XenoPort, Inc., its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with XenoPort’s 2014 Annual Meeting of Stockholders. XenoPort has filed with the SEC and provided to its stockhol

  4. Slide 4: Clinton's Agenda

    Clinton’s Agenda Clinton expressed disagreement with XenoPort Board’s capital allocation decisions Proposed in October 2013 and continues to recommend that XenoPort stop the commercialization of HORIZANT Insists that XenoPort focus all of its resources on XP23829, a compound that has yet to enter cl

  5. Slide 5: Agenda

    Agenda XenoPort overview Creating value in HORIZANT® XP23829 development execution Monetizing/creating opportunity for other assets XenoPort’s Board recommendations May 2014 XenoPort Investor Presentation 5

  6. Slide 6: XenoPort Overview

    XenoPort Overview

  7. Slide 7: Background on XenoPort

    Background on XenoPort Founded in 1999; IPO in 2005 92 full-time employees at December 31, 2013 Developed innovative biology/chemistry platform to improve drug efficacy, tolerability, compliance Discovered and developed 4 patented mid/late stage or marketed compounds May 2014 XenoPort Investor Prese

  8. Slide 8: Financials

    Financials $122.5 million of cash, cash equivalents and short-term investments at 3/31/14 Operations expected to be funded through 2015 Additional $25 million in non-dilutive cash expected in 2014 associated with licensing agreement announced 5/15/14* No debt All financial data as of March 31, 2014.

  9. Slide 9: Experienced Management Team

    Experienced Management Team Ronald W. Barrett, Ph.D. Chief Executive Officer Founder, former Chief Scientific Officer. More than 25 years of executive management and R&D experience in the pharmaceutical industry, Glaxo, Affymax, Abbott Dave Savello, Ph.D. Richard Kim, M.D. Senior VP of Senior VP, Ch

  10. Slide 10: XenoPort's Current Board Members are Independent, Qualified and Active

    XenoPort’s Current Board Members are Independent, Qualified and Active 9 highly-qualified and proven leaders 8 independent directors 3 new directors have joined the Board over the past 5 years Average tenure of 8.7 years versus average of ~10.1 years for the S&P 500, ~10.8 years for the S&P 1500, ~1

  11. Slide 11: Board with Proven Records, Relevant Experience and Broad Skill Sets

    Board with Proven Records, Relevant Experience and Broad Skill Sets John Freund, M.D., Lead Independent Director Managing Director: Skyline Ventures Partner: Chancellor Capital (INVESCO). Morgan Stanley Venture Partners Co-founder: Intuitive Surgical Former Executive: Acuson Ronald Barrett, Ph.D. Je

  12. Slide 12: XenoPort Success Rate in Mid/Late Stage Trials Exceeds Industry Norms

    XenoPort Success Rate in Mid/Late Stage Trials Exceeds Industry Norms XenoPort Phase 3 Trials • HORIZANT approved on 4 trials 3 positive 1 negative and… the basis of successful Phase 3 program XenoPort Phase 2 Trials • XP21279 study had trend 11 trials 7 positive 4 negative but… to positive outcome

  13. Slide 13: Management and Board Have Made Tough Decisions in Response to Setbacks

    Management and Board Have Made Tough Decisions in Response to Setbacks In response to HORIZANT Complete Response Letter • Moved rapidly to restructure around securing approval of HORIZANT and advancing its clinical-stage assets • Conserved resources • Reduced headcount by approximately 50% • Elimina

  14. Slide 14: Pay for Performance Philosophy: CEO Compensation Aligned with Performance and Peers

    Pay for Performance Philosophy: CEO Compensation Aligned with Performance and Peers • Compensation composed of salary, cash bonus and long-term incentives • Pay-for-performance philosophy and practice * Minimum Corporate Goal performance required for any bonus payment * Performance-basedequity grant

  15. Slide 15: Strategy to Build Stockholder Value

    Strategy to Build Stockholder Value Advance development of XP23829 as potential treatment for psoriasis and/or relapsing forms of multiple sclerosis Build significant value for HORIZANT • Provide funding source to capture the most value for XP23829 • Potential revenue through out-licensing deal or t

  16. Slide 16: Existing Stockholders Participated in January 2014 Financing

    Existing Stockholders Participated in January 2014 Financing XenoPort regularly meets with stockholders and potential new investors XenoPort Board members met with majority of top 15 stockholders in January 2014 prior to financing to get feedback on Clinton’s demands and XenoPort’s strategy Majority

  17. Slide 17: Industry Analysts are Supportive of the Actions XenoPort is Taking on HORIZANT

    Industry Analysts are Supportive of the Actions XenoPort is Taking on HORIZANT Industry analysts recognize the value potential of HORIZANT “We continue to see HORIZANT ($2.7 million in revenues in Q4 2013) as contributing modestly to XNPT valuation. However, if XNPT continues to execute well, we bel

  18. Slide 18: Creating Value in HORIZANT (gabapentin enacarbil) Extended-Release Tablets

    Creating Value in HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets

  19. Slide 19: We Re-Launched HORIZANT Less Than a Year Ago

    We Re-Launched HORIZANT Less Than a Year Ago HORIZANT – Discovered and Developed by XenoPort for RLS prior to 2007 FDA Approves FDA Approves HORIZANT for HORIZANT for Moderate-to-Severe Management of PHN Primary RLS in In Adults Adults HORIZANT Agreement Terminated XenoPort and Former XenoPort Partn

  20. Slide 20: Moderate-to-Severe Primary RLS Market Opportunity in U.S.

    Moderate-to-Severe Primary RLS Market Opportunity in U.S. Over 5 million adults suffer from moderate-to-severe primary restless legs syndrome (RLS) >6 million annual prescription Widespread use of dopamine agonists Growing awareness of issues related to dopamine agonist use in treatment of RLS Sourc

  21. Slide 21: HORIZANT Is Differentiated for RLS

    HORIZANT Is Differentiated for RLS Only non-dopamine agonist approved for treatment of moderate-to-severe primary RLS in adults Proven effective in relieving RLS symptoms HORIZANT is “not interchangeable with other gabapentin products” (FDA Label) Convenient once-a-day dosing No titration to approve

  22. Slide 22: RLS Treatment Guidelines Revised Since HORIZANT Approval

    RLS Treatment Guidelines Revised Since HORIZANT Approval International RLS Study Group Task Force recommends that ligands should be considered for first-line treatment for patients with RLS Willis Ekbom Disease Foundation Medical Advisory Board revised consensus statement on the management of RLS re

  23. Slide 23: Postherpetic Neuralgia (PHN)

    Postherpetic Neuralgia (PHN) Results from damage that occurs to the peripheral nerve fibers during a shingles outbreak Pain associated with PHN can be very intense About 200,000 patients suffer from PHN in the U.S. Clear unmet medical need • Only ~30% of patients receive 50% reduction in PHN pain wi

  24. Slide 24: HORIZANT is Differentiated for PHN

    HORIZANT is Differentiated for PHN Simple dosing • Three days at 600 mg once a day th • 4 day at approved 600 mg twice daily Effective at one week Pharmacokinetic differentiation • High bioavailability (75%) • Sustained 24-hour gabapentin blood levels (Peak/Trough = 1.5) • “Not interchangeable with

  25. Slide 25: HORIZANT: What Went Wrong with Former Partner?

    HORIZANT: What Went Wrong with Former Partner? Change in former partner’s CEO – HORIZANT champions departed Change in former partner’s development strategy • Partner exited pain development which was a major part of HORIZANT life cycle planning Government investigation of former partner’s past marke

  26. Slide 26: XenoPort's Initial Strategy: Demonstrate that HORIZANT is Promotionally Responsive

    XenoPort’s Initial Strategy Demonstrate that HORIZANT is Promotionally Responsive Strategy • Measure responsiveness quickly and efficiently • Build value in HORIZANT to provide strategic optionality (monetize or grow business) • Closely monitor results to make sure continued investment is warranted

  27. Slide 27: Solid HORIZANT Prescription Performance in 1Q 2014

    Solid HORIZANT Prescription Performance in 1Q 2014 National Prescribed Tablets XP Territories Prescribed Tablets 800,000 800,000 746,729 700,000 +24% 700,000 601,201 588,434 600,000 600,000 XNPT 40 500,000 sales 500,000 +64% 400,000 Former reps 400,000 359,685 partner 300,000 300,000 300 200,000 sal

  28. Slide 28: HORIZANT Prescription Growth Coming from XenoPort Promotion

    HORIZANT Prescription Growth Coming from XenoPort Promotion Weekly HORIZANT Prescribed Tablets 70,000 Previous XenoPort 63,599 Partner Commercialization 60,000 Stockout Begins 50,000 XenoPort Promoted 40,000 Territories 30,000 20,000 13,506 10,000 Non-Promoted Territories 0 May 2014 XenoPort Investo

  29. Slide 29: Physicians Now Receiving RLS AND PHN Promotional Messages

    Physicians Now Receiving RLS AND PHN Promotional Messages Former Partner Never Launched for PHN Indication 2500 Monthly HORIZANT TRx by Specialty 2000 XenoPort Begins Promotion PCP 1500 Neuro Psych PUD/Sleep Pain/Anes 1000 Other 500 0 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oc

  30. Slide 30: HORIZANT Gross Demand Sales at ~$25 Million Annualized Run Rate and Ramping

    HORIZANT Gross Demand Sales at ~$25 Million Annualized Run Rate and Ramping 4-Week Rolling Average - HORIZANT Prescribed Tablets May 31, 2013 to May 9, 2014 80,000 69,645 60,000 40,000 69,645 tablets at current WAC price = $489,125 / week 20,000 Achieved with 40 sales reps promoting to physicians th

  31. Slide 31: HORIZANT Summary

    HORIZANT Summary Our focused effort has demonstrated promising promotional responsiveness HORIZANT is now appropriately priced to be competitive with branded peers • Prescriptions remain robust after price increases • This value has accrued to XenoPort stockholders because we still own the product H

  32. Slide 32: XP23829 Development Execution

    XP23829 Development Execution

  33. Slide 33: Background: Fumaric Acid Ester Products

    Background: Fumaric Acid Ester Products FUMADERM (mixture of dimethylfumarate and monoethyl fumarate salts) • Approved in 1990s and widely used for the treatment of psoriasis in Germany TECFIDERA (dimethylfumarate) • Approved in March 2013 in the United States and February 2013 in EU for the treatme

  34. Slide 34: Potential Advantages and Areas of Differentiation

    Potential Advantages and Areas of Differentiation Lower incidence/less severe GI side effects and flushing • Improved compliance; fewer treatment failures Onset and/or magnitude of efficacy • Earlier onset of immunomodulation Reduced dosing frequency • Once a day rather than twice (TECFIDERA) or thr

  35. Slide 35: Ramping Investment in XP23829 Appropriate for its Stage of Development

    Ramping Investment in XP23829 Appropriate for its Stage of Development Completed numerous preclinical studies Most studies included DMF for comparison Animals studies demonstrated less gastric irritation Phase 1 data has demonstrated favorable pharmacokinetic and pharmacodynamic effects Included dir

  36. Slide 36: XP23829 has Inherent Risk, Like All Drug Candidates

    XP23829 has Inherent Risk, Like All Drug Candidates Lymphocyte reductions require further exploration • Psoriasis Phase 2 study is designed to establish whether XP23829 differs from FUMADERM/TECFIDERA and to assess the potential benefits and risks if different TECFIDERA’s patents likely to be challe

  37. Slide 37: Monetizing/Creating Opportunity for Other Assets

    Monetizing/Creating Opportunity for Other Assets

  38. Slide 38: AP Agreement Creates Value for XenoPort Stockholders

    AP Agreement Creates Value for XenoPort Stockholders Exclusive world-wide rights granted to Reckitt Benckiser Pharmaceuticals announced on May 15, 2014 1 Initial development focus: Alcohol Use Disorder $20 million up-front plus $5 million on technology transfer completion Up to $70 million in develo

  39. Slide 39: XenoPort's Board Recommendations

    XenoPort’s Board Recommendations

  40. Slide 40: XenoPort Board Engagement with Clinton

    XenoPort Board Engagement with Clinton June 2013: Clinton began buying and selling XenoPort shares. October 2013: Clinton issues public letter attacking performance and leadership, and demanding replacement of XenoPort’s CEO. Fall – Winter 2013: Members of XenoPort’s Board and management have confer

  41. Slide 41: XenoPort Board Engagement with Clinton (con't)

    XenoPort Board Engagement with Clinton (con’t) February 2014: Members of XenoPort’s Board engage in multiple discussions with Clinton in an effort to reach a resolution and avoid a costly and disruptive proxy battle. March 2014: Clinton does not respond to XenoPort’s modified settlement proposal. Ap

  42. Slide 42: Clinton's Agenda for Capital Allocation Could Destroy Value

    Clinton’s Agenda for Capital Allocation Could Destroy Value Now is the worst time to abandon HORIZANT commercialization • Investment in commercial operations is complete • Investments in marketing initiatives and programs are largely committed • Positive trajectory of sales is increasing the value o

  43. Slide 43: Clinton's Agenda to Replace XenoPort CEO and Two Highly-Qualified Directors Could Destroy Value

    Clinton’s Agenda to Replace XenoPort CEO and Two Highly-Qualified Directors Could Destroy Value Clinton Agenda: replace the CEO Dr. Barrett has played, and will continue to play, a pivotal role in executing XenoPort’s strategy Clinton has not identified or proposed an alternative CEO. Dismissing cur

  44. Slide 44: Director Nominees Provide Expertise Critical to XenoPort's Success

    Director Nominees Provide Expertise Critical to XenoPort’s Success Ronald W. Barrett, Ph.D. Chief Executive Officer of XenoPort since 2001 20+ years of executive management experience in the pharmaceutical industry Chief Scientific Officer of XenoPort from 1999 to 2001 Various positions at Affymax R

  45. Slide 45: Director Nominees Provide Expertise Critical to XenoPort's Success

    Director Nominees Provide Expertise Critical to XenoPort’s Success Jeryl L. Hilleman Chair of XenoPort Audit Committee 30+ years of finance, marketing and investment experience and an impressive history of executive leadership 20+ years as CFO of both private and public companies Ms. Hilleman’s cons

  46. Slide 46: Director Nominees Provide Expertise Critical to XenoPort's Success

    Director Nominees Provide Expertise Critical to XenoPort’s Success Wendell Wierenga, Ph.D. 40 years of leadership of pharmaceutical and biopharmaceutical companies, including Executive leadership of pharmaceutical research, clinical development and regulatory functions for a number of national and m

  47. Slide 47: The Right Strategy and Board to Execute and Deliver Long-Term Value

    The Right Strategy and Board to Execute and Deliver Long-Term Value XenoPort Is Committed to Realizing the Full Potential of its Assets and Acting in the Best Interests of XenoPort Stockholders. Our Board is active and engaged, and has the depth and diversity of skills and expertise needed to overse

  48. Slide 48: HORIZANT: Important Safety Information

    HORIZANT: Important Safety Information HORIZANT® (gabapentin enacarbil) Extended-ReleaseTablets INDICATIONS HORIZANT® (gabapentin enacarbil) is a prescription medicine used to: treat adults with moderate-to-severe primary Restless Legs Syndrome (RLS). HORIZANT is not for people who need to sleep dur

  49. Slide 49: HORIZANT: Important Safety Information

    HORIZANT: Important Safety Information HORIZANTis not the same medicine as gabapentin(for example, Neurontin® and Gralise® ). HORIZANT should not be used in their place. Do not take these or other gabapentin products while taking HORIZANT. Before taking HORIZANT, tell your healthcare provider if you

Xenoport — Proxy Contest (May 2014) on 6ix